Drugging Chromatin in Cancer: Recent Advances and Novel Approaches

Molecular Cell

Volumn 60, Issue 4, 2015, Pages 561-570

  Cai, Sheng F ^a   Chen, Chun Wei ^a   Armstrong, Scott A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; AZACITIDINE; DECITABINE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; IPILIMUMAB; JUMONJI D3; LENALIDOMIDE; LYSINE SPECIFIC DEMETHYLASE 1; METHIONINE; NIVOLUMAB; PROTEIN; RETINOIC ACID; TRANSCRIPTION FACTOR EZH2; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; CHROMATIN;

ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; CELL DIFFERENTIATION; CHROMATIN; CHROMATIN STRUCTURE; CHROMOSOME TRANSLOCATION; CYTOKINE PRODUCTION; DNA METHYLATION; DRUG RESISTANCE; ENHANCER REGION; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; UPREGULATION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CHROMATIN; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84947787152     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.10.042     Document Type: Review

References (102)

1. Ahuja N., Easwaran H., Baylin S.B. Harnessing the potential of epigenetic therapy to target solid tumors. J. Clin. Invest. 2014, 124:56-63.
2. Aldawsari F.S., Aguayo-Ortiz R., Kapilashrami K., Yoo J., Luo M., Medina-Franco J.L., Velazquez-Martinez C.A. Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents. J. Enz. Inhibi. Med. Chem. 2015, 10.3109/14756366.2015.1058256.
3. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P., Akslen L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 2006, 24:268-273.
4. Basheer F., Huntly B.J. BET bromodomain inhibitors in leukemia. Exp. Hematol. 2015, 43:718-731.
5. Bernstein B.E., Stamatoyannopoulos J.A., Costello J.F., Ren B., Milosavljevic A., Meissner A., Kellis M., Marra M.A., Beaudet A.L., Ecker J.R., et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat. Biotechnol. 2010, 28:1045-1048.
6. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
7. Borkin D., He S., Miao H., Kempinska K., Pollock J., Chase J., Purohit T., Malik B., Zhao T., Wang J., et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 2015, 27:589-602.
8. Campbell J.E., Kuntz K.W., Knutson S.K., Warholic N.M., Keilhack H., Wigle T.J., Raimondi A., Klaus C.R., Rioux N., Yokoi A., et al. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Med. Chem. Lett. 2015, 6:491-495.
9. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
10. Cao F., Townsend E.C., Karatas H., Xu J., Li L., Lee S., Liu L., Chen Y., Ouillette P., Zhu J., et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 2014, 53:247-261.
11. Chen C.W., Koche R.P., Sinha A.U., Deshpande A.J., Zhu N., Eng R., Doench J.G., Xu H., Chu S.H., Qi J., et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 2015, 21:335-343.
12. Consortium E.P. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 2004, 306:636-640. ENCODE Project Consortium.
13. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
14. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
15. Deshpande A.J., Bradner J., Armstrong S.A. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 2012, 33:563-570.
16. Deshpande A.J., Deshpande A., Sinha A.U., Chen L., Chang J., Cihan A., Fazio M., Chen C.W., Zhu N., Koche R., et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell 2014, 26:896-908.
17. Dixon J.R., Selvaraj S., Yue F., Kim A., Li Y., Shen Y., Hu M., Liu J.S., Ren B. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 2012, 485:376-380.
18. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
19. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 2014, 13:673-691.
20. Filippakopoulos P., Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 2014, 13:337-356.
21. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
22. Fillmore C.M., Xu C., Desai P.T., Berry J.M., Rowbotham S.P., Lin Y.J., Zhang H., Marquez V.E., Hammerman P.S., Wong K.K., Kim C.F. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 2015, 520:239-242.
23. Fiskus W., Wang Y., Sreekumar A., Buckley K.M., Shi H., Jillella A., Ustun C., Rao R., Fernandez P., Chen J., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
24. Fiskus W., Sharma S., Shah B., Portier B.P., Devaraj S.G., Liu K., Iyer S.P., Bearss D., Bhalla K.N. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 2014, 28:2155-2164.
25. French C.A. Pathogenesis of NUT midline carcinoma. Annu. Rev. Pathol. 2012, 7:247-265.
26. Funato K., Major T., Lewis P.W., Allis C.D., Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 2014, 346:1529-1533.
27. Galm O., Herman J.G., Baylin S.B. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006, 20:1-13.
28. Gao X.N., Lin J., Ning Q.Y., Gao L., Yao Y.S., Zhou J.H., Li Y.H., Wang L.L., Yu L. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PloS One 2013, 8:e55481.
29. Giotopoulos G., Chan W.I., Horton S.J., Ruau D., Gallipoli P., Fowler A., Crawley C., Papaemmanuil E., Campbell P.J., Göttgens B., et al. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene 2015, 10.1038/onc.2015.92.
30. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
31. Grembecka J., Belcher A.M., Hartley T., Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J. Biol. Chem. 2010, 285:40690-40698.
32. Grembecka J., He S., Shi A., Purohit T., Muntean A.G., Sorenson R.J., Showalter H.D., Murai M.J., Belcher A.M., Hartley T., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 2012, 8:277-284.
33. Guenther M.G., Lawton L.N., Rozovskaia T., Frampton G.M., Levine S.S., Volkert T.L., Croce C.M., Nakamura T., Canaani E., Young R.A. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008, 22:3403-3408.
34. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., Ciceri F., Blaser J.G., Greystoke B.F., Jordan A.M., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
35. Herranz D., Ambesi-Impiombato A., Palomero T., Schnell S.A., Belver L., Wendorff A.A., Xu L., Castillo-Martin M., Llobet-Navás D., Cordon-Cardo C., et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat. Med. 2014, 20:1130-1137.
36. Hughes C.M., Rozenblatt-Rosen O., Milne T.A., Copeland T.D., Levine S.S., Lee J.C., Hayes D.N., Shanmugam K.S., Bhattacharjee A., Biondi C.A., et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 2004, 13:587-597.
37. Jo S.Y., Granowicz E.M., Maillard I., Thomas D., Hess J.L. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011, 117:4759-4768.
38. Juergens R.A., Wrangle J., Vendetti F.P., Murphy S.C., Zhao M., Coleman B., Sebree R., Rodgers K., Hooker C.M., Franco N., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1:598-607.
39. Kadoch C., Hargreaves D.C., Hodges C., Elias L., Ho L., Ranish J., Crabtree G.R. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 2013, 45:592-601.
40. Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.L., Leighton J.K., Patel H., Rahman A., Sridhara R., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 2005, 11:3604-3608.
41. Khan S.N., Jankowska A.M., Mahfouz R., Dunbar A.J., Sugimoto Y., Hosono N., Hu Z., Cheriyath V., Vatolin S., Przychodzen B., et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 2013, 27:1301-1309.
42. Kim W., Bird G.H., Neff T., Guo G., Kerenyi M.A., Walensky L.D., Orkin S.H. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 2013, 9:643-650.
43. Knoechel B., Roderick J.E., Williamson K.E., Zhu J., Lohr J.G., Cotton M.J., Gillespie S.M., Fernandez D., Ku M., Wang H., et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 2014, 46:364-370.
44. Knutson S.K., Warholic N.M., Wigle T.J., Klaus C.R., Allain C.J., Raimondi A., Porter Scott M., Chesworth R., Moyer M.P., Copeland R.A., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 2013, 110:7922-7927.
45. Knutson S.K., Kawano S., Minoshima Y., Warholic N.M., Huang K.C., Xiao Y., Kadowaki T., Uesugi M., Kuznetsov G., Kumar N., et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 2014, 13:842-854.
46. Knutson S.K., Warholic N.M., Johnston L.D., Klaus C.R., Wigle T.J., Iwanowicz D., Littlefield B.A., Porter-Scott M., Smith J.J., Moyer M.P., et al. Synergistic anti-tumor activity of EZH2 inhibitors and glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphomas. PLoS ONE 2014, 9:e111840.
47. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., Xia X., Jesneck J., Bracken A.P., Silverman L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
48. Kuntimaddi A., Achille N.J., Thorpe J., Lokken A.A., Singh R., Hemenway C.S., Adli M., Zeleznik-Le N.J., Bushweller J.H. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. Cell Rep. 2015, 11:808-820.
49. Li H., Chiappinelli K.B., Guzzetta A.A., Easwaran H., Yen R.W., Vatapalli R., Topper M.J., Luo J., Connolly R.M., Azad N.S., et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014, 5:587-598.
50. Li Y., Wen H., Xi Y., Tanaka K., Wang H., Peng D., Ren Y., Jin Q., Dent S.Y., Li W., et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 2014, 159:558-571.
51. Lin C., Smith E.R., Takahashi H., Lai K.C., Martin-Brown S., Florens L., Washburn M.P., Conaway J.W., Conaway R.C., Shilatifard A. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 2010, 37:429-437.
52. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
53. Lupiáñez D.G., Kraft K., Heinrich V., Krawitz P., Brancati F., Klopocki E., Horn D., Kayserili H., Opitz J.M., Laxova R., et al. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. Cell 2015, 161:1012-1025.
54. Lv T., Yuan D., Miao X., Lv Y., Zhan P., Shen X., Song Y. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS ONE 2012, 7:e35065.
55. Malik R., Khan A.P., Asangani I.A., Cieślik M., Prensner J.R., Wang X., Iyer M.K., Jiang X., Borkin D., Escara-Wilke J., et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat. Med. 2015, 21:344-352.
56. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
57. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
58. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 2011, 108:16669-16674.
59. Metzger E., Wissmann M., Yin N., Müller J.M., Schneider R., Peters A.H., Günther T., Buettner R., Schüle R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437:436-439.
60. Meyer C., Hofmann J., Burmeister T., Gröger D., Park T.S., Emerenciano M., Pombo de Oliveira M., Renneville A., Villarese P., Macintyre E., et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013, 27:2165-2176.
61. Mohammad H.P., Smitheman K.N., Kamat C.D., Soong D., Federowicz K.E., Van Aller G.S., Schneck J.L., Carson J.D., Liu Y., Butticello M., et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 2015, 28:57-69.
62. Mohan M., Lin C., Guest E., Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat. Rev. Cancer 2010, 10:721-728.
63. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
64. Neff T., Sinha A.U., Kluk M.J., Zhu N., Khattab M.H., Stein L., Xie H., Orkin S.H., Armstrong S.A. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc. Natl. Acad. Sci. USA 2012, 109:5028-5033.
65. Nguyen A.T., Taranova O., He J., Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 2011, 117:6912-6922.
66. Ntziachristos P., Tsirigos A., Van Vlierberghe P., Nedjic J., Trimarchi T., Flaherty M.S., Ferres-Marco D., da Ros V., Tang Z., Siegle J., et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 2012, 18:298-301.
67. Ntziachristos P., Tsirigos A., Welstead G.G., Trimarchi T., Bakogianni S., Xu L., Loizou E., Holmfeldt L., Strikoudis A., King B., et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 2014, 514:513-517.
68. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L., Xu G., Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
69. Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., Kasper L.H., Lerach S., Tang H., Ma J., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
70. Piekarz R.L., Frye R., Prince H.M., Kirschbaum M.H., Zain J., Allen S.L., Jaffe E.S., Ling A., Turner M., Peer C.J., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
71. Richon V.M., Zhou X., Rifkind R.A., Marks P.A. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 2001, 27:260-264.
72. Roberts C.W., Galusha S.A., McMenamin M.E., Fletcher C.D., Orkin S.H. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl. Acad. Sci. USA 2000, 97:13796-13800.
73. Roe J.S., Mercan F., Rivera K., Pappin D.J., Vakoc C.R. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol. Cell 2015, 58:1028-1039.
74. San-Miguel J.F., Hungria V.T., Yoon S.S., Beksac M., Dimopoulos M.A., Elghandour A., Jedrzejczak W.W., Gunther A., Nakorn T.N., Siritanaratkul N., et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014, 15:1195-1206.
75. Santer F.R., Hoschele P.P., Oh S.J., Erb H.H., Bouchal J., Cavarretta I.T., Parson W., Meyers D.J., Cole P.A., Culig Z. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol. Cancer Therapeutics 2011, 10:1644-1655.
76. Sarkaria S.M., Christopher M.J., Klco J.M., Ley T.J. Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia 2014, 28:2403-2406.
77. Schenk T., Chen W.C., Göllner S., Howell L., Jin L., Hebestreit K., Klein H.U., Popescu A.C., Burnett A., Mills K., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 2012, 18:605-611.
78. Shain A.H., Pollack J.R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 2013, 8:e55119.
79. Shalem O., Sanjana N.E., Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 2015, 16:299-311.
80. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
81. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A., Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
82. Shi A., Murai M.J., He S., Lund G., Hartley T., Purohit T., Reddy G., Chruszcz M., Grembecka J., Cierpicki T. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 2012, 120:4461-4469.
83. Shi J., Wang E., Milazzo J.P., Wang Z., Kinney J.B., Vakoc C.R. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat. Biotechnol. 2015, 33:661-667.
84. Smith E., Lin C., Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 2011, 25:661-672.
85. Steger D.J., Lefterova M.I., Ying L., Stonestrom A.J., Schupp M., Zhuo D., Vakoc A.L., Kim J.E., Chen J., Lazar M.A., et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell. Biol. 2008, 28:2825-2839.
86. Stein, E.M., Garcia-Manero, G., Rizzieri, D.A., Savona, M., Tibes, R., Altman, J.K., Jongen-Lavrencic, M., Döhner, H., Armstrong, S., Pollock, R.M., et al. (2014). The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia. 56th American Society of Hematology Annual Meeting and Exposition; San Francisco, CA.
87. Stockman D.L., Curry J.L., Torres-Cabala C.A., Watson I.R., Siroy A.E., Bassett R.L., Zou L., Patel K.P., Luthra R., Davies M.A., et al. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J. Cutan. Pathol. 2015, 42:308-317.
88. Stratikopoulos E.E., Dendy M., Szabolcs M., Khaykin A.J., Lefebvre C., Zhou M.M., Parsons R. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell 2015, 27:837-851.
89. Sullivan L.M., Folpe A.L., Pawel B.R., Judkins A.R., Biegel J.A. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Modern Pathology 2013, 26:385-392.
90. Tanaka M., Roberts J.M., Qi J., Bradner J.E. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). Pharm. Pat. Anal. 2015, 4:261-284.
91. Thiel A.T., Blessington P., Zou T., Feather D., Wu X., Yan J., Zhang H., Liu Z., Ernst P., Koretzky G.A., Hua X. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010, 17:148-159.
92. Tsai H.C., Li H., Van Neste L., Cai Y., Robert C., Rassool F.V., Shin J.J., Harbom K.M., Beaty R., Pappou E., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21:430-446.
93. Versteege I., Sévenet N., Lange J., Rousseau-Merck M.F., Ambros P., Handgretinger R., Aurias A., Delattre O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998, 394:203-206.
94. Wagener N., Holland D., Bulkescher J., Crnkovic-Mertens I., Hoppe-Seyler K., Zentgraf H., Pritsch M., Buse S., Pfitzenmaier J., Haferkamp A., et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int. J. Cancer 2008, 123:1545-1550.
95. Wilson B.G., Wang X., Shen X., McKenna E.S., Lemieux M.E., Cho Y.J., Koellhoffer E.C., Pomeroy S.L., Orkin S.H., Roberts C.W. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010, 18:316-328.
96. Winter G.E., Buckley D.L., Paulk J., Roberts J.M., Souza A., Dhe-Paganon S., Bradner J.E. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 2015, 348:1376-1381.
97. Yashiro-Ohtani Y., Wang H., Zang C., Arnett K.L., Bailis W., Ho Y., Knoechel B., Lanauze C., Louis L., Forsyth K.S., et al. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proc. Natl. Acad. Sci. USA 2014, 111:E4946-E4953.
98. Yokoyama A., Somervaille T.C., Smith K.S., Rozenblatt-Rosen O., Meyerson M., Cleary M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123:207-218.
99. You J.S., Jones P.A. Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell 2012, 22:9-20.
100. Zhang B., Strauss A.C., Chu S., Li M., Ho Y., Shiang K.D., Snyder D.S., Huettner C.S., Shultz L., Holyoake T., Bhatia R. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010, 17:427-442.
101. Zhou H., Liu L., Huang J., Bernard D., Karatas H., Navarro A., Lei M., Wang S. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. J. Med. Chem. 2013, 56:1113-1123.
102. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.